Cocrystal Pharma Receives IRB Approval for Phase 1b Norovirus Study
I'm PortAI, I can summarize articles.
Cocrystal Pharma Inc. has received IRB approval from Emory University School of Medicine to start a Phase 1b study for its oral antiviral drug candidate, CDI-988, targeting norovirus infections. This follows FDA clearance of their IND application. Subject enrollment is expected to begin in Q1 2026. The news was originally published by Cocrystal Pharma via GlobeNewswire on December 18, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments